Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw materials based in the Netherlands. Pharmavit Europe supplies high- ...

Core Insights - Fagron reported a strong performance in FY 2025 with a 9.2% topline growth and a 10.9% increase in REBITDA [1][6] Financial Performance - Revenue reached €952.2 million, exceeding guidance, with a reported growth of 9.2% (12.9% at constant exchange rates) [7] - Organic growth at constant exchange rates was 9.1%, driven by sustained underlying demand and disciplined commercial execution [7] - REBITDA increased by 10.9% year-over-year to €192.9 million, resulting in a REBITDA margin of 20.3% [7] - Operating cash flow was €155.3 million, with free cash flow of €125.9 million, reflecting a 29.0% year-over-year increase [7] - The leverage ratio decreased to 1.2x from 1.4x in 2024, providing capacity for expansion capital expenditures and acquisitions [7] - Earnings per share (EPS) rose to €1.25, a 13.6% increase year-over-year, with a 9% compound annual growth rate over the last eight years [7] - A dividend proposal of €0.40 per share was made, marking a 14.3% increase year-over-year [7] Regional Performance - EMEA showed resilient performance due to geographical diversification and integration of recent acquisitions [4] - Latin America, particularly Brazil, maintained strong momentum driven by the Brands portfolio and innovation pipeline [4] - North America-Pacific benefited from outsourcing demand and onboarding new customers, alongside ongoing efficiency initiatives [4] Strategic Initiatives - The company experienced significant M&A activity, announcing 12 acquisitions across all regions and segments, with integration progressing as planned [5][7] - The company remains focused on execution and capturing synergies from acquisitions [5] - The outlook for FY 2026 includes mid- to high-single digit organic sales growth and slight margin improvement year-over-year [7]

Group 1 - Fagron has obtained regulatory clearance for the acquisition of Vepakum in Brazil and has completed the acquisition of Magilab in Hungary [1][9] - The acquisition of Vepakum will enable Fagron to enter a new vertical in high-quality packaging solutions, providing scale benefits through joint packaging, distribution, and shared services [2] - The acquisition of Magilab strengthens Fagron's position in Hungary's hospital pharmacy segment, which has a high compounding per capita, and supports operational leverage through integration and scale [3] Group 2 - Fagron is a leading global company in pharmaceutical compounding, focusing on personalized medicine delivery to hospitals, pharmacies, clinics, and patients in over 35 countries [5] - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [6]

Core Insights - Fagron has completed the acquisition of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder in California, enhancing its position in the health and wellness segment [1][2] - The acquisition is valued at approximately $41.5 million, with UCP generating annual revenues of around $25 million and an EBITDA margin lower than Fagron's existing group margin [3] - Fagron aims to realize synergies from the integration of UCP over the next 18 to 24 months, as part of its strategy to build a nationwide platform in the United States [3][4] Company Strategy - The acquisition of UCP complements Fagron's existing operations, particularly with Anazao, and strengthens its footprint in California, a highly regulated healthcare market [2][4] - Fagron has executed fourteen acquisitions across various regions recently, indicating a strategy of selective expansion and vertical integration [3][5] - The company remains focused on execution and integration of acquired businesses to build a larger, higher-quality compounding platform [5] Financial Outlook - Fagron's financial calendar includes key dates for full-year results, trading updates, and the annual general meeting, with the next full-year results scheduled for February 12, 2026 [5]

Core Insights - Fagron has successfully completed the acquisition of Purifarma in Brazil, marking a significant step in its M&A strategy and enhancing its scalable platform for long-term growth [1][2][3] Group 1: Acquisition Details - The acquisition of Purifarma, valued at approximately R$250 million, is expected to provide procurement benefits in Latin America and across Fagron's global operations [2] - Purifarma is recognized as a large-scale Essentials business with a competitive product portfolio and significant volumes, which will allow Fagron to improve its product mix and extend its reach to industrial clients [2][3] Group 2: Strategic Commentary - CEO Rafael Padilla emphasized that the completion of this acquisition strengthens Fagron's position in Brazil and aligns with its disciplined buy-and-build strategy, focusing on scale, procurement, and access to industrial clients [3] - The company aims to remain selective and execution-focused during the integration of Purifarma to build a larger and more efficient platform [3] Group 3: Company Overview - Fagron is a leading global company in pharmaceutical compounding, delivering personalized medicine to various healthcare providers in over 35 countries [5] - The company is headquartered in Nazareth, Belgium, and operates through its Dutch subsidiary, Fagron BV, which is based in Rotterdam [6]

Core Insights - Fagron is expanding its global presence through two strategic acquisitions: Amber Compounding Pharmacy in Singapore and Malaysia, and Vepakum in Brazil, enhancing its capabilities in the pharmaceutical compounding market [1][2] - The acquisitions are expected to generate approximately €26 million in annual revenue with an EBITDA margin exceeding the current group margin, at a total purchase price of around €55 million, resulting in an average EV to EBITDA multiple of about 8x [3] - Fagron has also secured a license for its Anazao Health facility in Tampa, allowing the shipment of compounded medications to California, which strengthens its position in the U.S. healthcare market [4][7] Acquisition Details - Amber Compounding Pharmacy operates five strategic locations in Singapore and Malaysia, recognized as a leader in the compounding market, serving clinics, hospital pharmacies, and distributors [5] - Vepakum, based in São Paulo, Brazil, provides high-quality packaging solutions, enabling Fagron to achieve scale benefits through joint packaging and distribution [6] Licensing and Operational Updates - The license obtained for the Tampa facility allows for the shipment of compounded medications on a prescription basis, marking a significant milestone in Fagron's nationwide platform for Health and Wellness services [7][8] - Following the licensing, all Fagron facilities in the U.S. can now ship compounded medications to California, significantly enhancing operational flexibility [9]

Core Insights - Fagron has strengthened its leadership in the EMEA region through acquisitions in Poland and Hungary, aligning with its strategy to diversify in dynamic markets and emphasizing its disciplined M&A approach for sustainable growth [1][2][8] Acquisitions - The acquisitions of Amara in Poland and Magilab in Hungary are expected to contribute mid-teens (€m) in annual revenue with an EBITDA margin exceeding Fagron's existing group margin, with a combined purchase price of approximately €26 million [2][4][5] - Amara brings over 30 years of experience in the Polish compounding sector and enhances Fagron's offerings while unlocking significant synergy potential [4] - Magilab is a trusted brand in Hungary's hospital pharmacy segment, consolidating Fagron's position in a market characterized by high compounding per capita [5] Financial Developments - Fagron has secured a new U.S. dollar credit facility totaling up to $225 million with maturities extending up to 15 years, enhancing financial flexibility and supporting growth ambitions in North America [6] - An initial $125 million has been drawn from this facility, which complements an existing €575 million bank facility [6] Licensing and Market Presence - Fagron has received a license for its Fagron Sterile Services facility in Boston, allowing the shipment of compounding medication to California, a significant step in reinforcing its presence in a major U.S. healthcare market [3][7] - This license enables all of Fagron's 503B facilities in the U.S. to ship to California, unlocking further opportunities with key customers [7] Strategic Vision - The CEO of Fagron highlighted that the acquisitions and financial developments are crucial for consolidating leadership in EMEA and supporting global ambitions in the B&E segment [8][9] - The company emphasizes its commitment to disciplined M&A, operational excellence, and prudent balance sheet management as key enablers of sustained growth and long-term success [10]

Group 1 - Fagron completed a share buy-back program, repurchasing a total of 200,000 shares at an average price of €20.6805, amounting to €4,136,093 [1][2] - The recent buy-back occurred from 10 November 2025 to 14 November 2025, during which 44,000 shares were bought at an average price of €20.7208, totaling €911,717 [1] - The buy-back program was announced on 9 October 2025, and the repurchased shares will be used to meet obligations under Fagron's long-term incentive scheme [2] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 35 countries [4] - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [5] - Operational activities are managed through Fagron BV, which is headquartered in Rotterdam [5] Group 3 - The financial calendar includes key dates such as the full year results for 2025 on 12 February 2026 and the trading update for the first quarter of 2026 on 9 April 2026 [3]

Group 1 - Fagron has initiated a share buy-back program, purchasing 20,000 shares at an average price of €20.609, totaling €412,180 from 16 October 2025 to 17 October 2025 [1] - The share buy-back program aims to fulfill obligations under Fagron's long-term incentive scheme, with a total of up to 200,000 shares planned for repurchase [1] - To date, Fagron has purchased a total of 20,000 shares under this program [1] Group 2 - Fagron is a global leader in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 30 countries [3] - The company is registered in Belgium and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Operational activities are managed by Fagron BV, headquartered in Rotterdam, Netherlands [4]

Core Insights - Fagron reported a solid third-quarter performance with a revenue growth of 6.4%, reaching €228.2 million, and confirmed its full-year revenue outlook of €930 – €950 million for 2025 [1][6][7] Group 1: Financial Performance - The company achieved an organic growth rate of 8.5% at constant exchange rates (CER) on a normalized basis, and 5.7% when accounting for the impact of GLP-1 drug shortages [7] - Revenue for Q3 2025 was €228.2 million, reflecting a 6.4% increase and a 10.3% increase at CER, driven by resilient structural drivers and focused commercial execution [7] Group 2: Regional Performance - EMEA showed broad-based progress across Brands, Essentials, and Compounding Services, with a mix of mature and growth markets responding positively to commercial efforts [3] - Latin America, particularly Brazil, continued strong momentum with targeted commercial activities and product launches supporting increased adoption [4] - North America remains a key growth engine, with planned capacity expansion and successful FDA inspections validating corrective actions [4] Group 3: M&A Activity - The company maintained momentum in mergers and acquisitions (M&A), signing University Compounding Pharmacy to strengthen its health and wellness platform in the U.S. [5] - Antitrust clearance for Purifarma and Injeplast in Brazil marks a significant milestone for expanding Fagron's portfolio and capabilities [5] - A total of eight acquisitions have been announced year-to-date, indicating ongoing strategic growth initiatives [7]